Literature DB >> 33431483

Inducible expression of human C9ORF72 36x G4C2 hexanucleotide repeats is sufficient to cause RAN translation and rapid muscular atrophy in mice.

F W Riemslagh1, E C van der Toorn2, R F M Verhagen2, A Maas3, L W J Bosman4, R K Hukema2, R Willemsen2.   

Abstract

The hexanucleotide G4C2 repeat expansion in the first intron of the C9ORF72 gene explains the majority of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) cases. Numerous studies have indicated the toxicity of dipeptide repeats (DPRs) which are produced via repeat-associated non-AUG (RAN) translation from the repeat expansion and accumulate in the brain of C9FTD/ALS patients. Mouse models expressing the human C9ORF72 repeat and/or DPRs show variable pathological, functional, and behavioral characteristics of FTD and ALS. Here, we report a new Tet-on inducible mouse model that expresses 36x pure G4C2 repeats with 100bp upstream and downstream human flanking regions. Brain specific expression causes the formation of sporadic sense DPRs aggregates upon 6 months dox induction but no apparent neurodegeneration. Expression in the rest of the body evokes abundant sense DPRs in multiple organs, leading to weight loss, neuromuscular junction disruption, myopathy, and a locomotor phenotype within the time frame of four weeks. We did not observe any RNA foci or pTDP-43 pathology. Accumulation of DPRs and the myopathy phenotype could be prevented when 36x G4C2 repeat expression was stopped after 1 week. After 2 weeks of expression, the phenotype could not be reversed, even though DPR levels were reduced. In conclusion, expression of 36x pure G4C2 repeats including 100bp human flanking regions is sufficient for RAN translation of sense DPRs and evokes a functional locomotor phenotype. Our inducible mouse model suggests early diagnosis and treatment are important for C9FTD/ALS patients.
© 2021. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  ALS; C9ORF72; DPRs; FTD; Inducible; Mouse

Year:  2021        PMID: 33431483      PMCID: PMC7903916          DOI: 10.1242/dmm.044842

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


  83 in total

1.  Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death.

Authors:  Chantal Sellier; Maria-Letizia Campanari; Camille Julie Corbier; Angeline Gaucherot; Isabelle Kolb-Cheynel; Mustapha Oulad-Abdelghani; Frank Ruffenach; Adeline Page; Sorana Ciura; Edor Kabashi; Nicolas Charlet-Berguerand
Journal:  EMBO J       Date:  2016-04-21       Impact factor: 11.598

2.  Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.

Authors:  Jiaxin Hu; Frank Rigo; Thazha P Prakash; David R Corey
Journal:  Nucleic Acid Ther       Date:  2016-12-22       Impact factor: 5.486

3.  c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA.

Authors:  Jing Liu; Jiaxin Hu; Andrew T Ludlow; Jacqueline T Pham; Jerry W Shay; Jeffrey D Rothstein; David R Corey
Journal:  Cell Chem Biol       Date:  2017-01-26       Impact factor: 8.116

4.  Pharmacokinetics and tissue localization of doxycycline polyphosphate and doxycycline hydrochloride in the rat.

Authors:  G Michel; J Mosser; J Olle
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

5.  C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD.

Authors:  Jacqueline G O'Rourke; Laurent Bogdanik; A K M G Muhammad; Tania F Gendron; Kevin J Kim; Andrew Austin; Janet Cady; Elaine Y Liu; Jonah Zarrow; Sharday Grant; Ritchie Ho; Shaughn Bell; Sharon Carmona; Megan Simpkinson; Deepti Lall; Kathryn Wu; Lillian Daughrity; Dennis W Dickson; Matthew B Harms; Leonard Petrucelli; Edward B Lee; Cathleen M Lutz; Robert H Baloh
Journal:  Neuron       Date:  2015-12-02       Impact factor: 17.173

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 7.  C9orf72-mediated ALS and FTD: multiple pathways to disease.

Authors:  Rubika Balendra; Adrian M Isaacs
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

8.  Accumulation of dipeptide repeat proteins predates that of TDP-43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene.

Authors:  Atik Baborie; Timothy D Griffiths; Evelyn Jaros; Robert Perry; Ian G McKeith; David J Burn; Masami Masuda-Suzukake; Masato Hasegawa; Sara Rollinson; Stuart Pickering-Brown; Andrew C Robinson; Yvonne S Davidson; David M A Mann
Journal:  Neuropathol Appl Neurobiol       Date:  2015-04-30       Impact factor: 8.090

9.  Ubiquitous expression of the rtTA2S-M2 inducible system in transgenic mice driven by the human hnRNPA2B1/CBX3 CpG island.

Authors:  Eleni Z Katsantoni; Nora E Anghelescu; Robbert Rottier; Matthijs Moerland; Michael Antoniou; Rini de Crom; Frank Grosveld; John Strouboulis
Journal:  BMC Dev Biol       Date:  2007-09-27       Impact factor: 1.978

10.  Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity.

Authors:  Lauren M Gittings; Steven Boeynaems; Daniel Lightwood; Alison Clargo; Sarfaraj Topia; Lisa Nakayama; Claire Troakes; David M A Mann; Aaron D Gitler; Tammaryn Lashley; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2019-12-12       Impact factor: 17.088

View more
  2 in total

Review 1.  Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease.

Authors:  Pauline A Gelon; Paul A Dutchak; Chantelle F Sephton
Journal:  Front Mol Neurosci       Date:  2022-10-03       Impact factor: 6.261

Review 2.  Small junction, big problems: Neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS).

Authors:  Abrar Alhindi; Ines Boehm; Helena Chaytow
Journal:  J Anat       Date:  2021-06-07       Impact factor: 2.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.